Where is Aurigene located?

Aurigene is headquartered in Bengaluru, India. It is registered at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Hyderabad, Telangana, India, 500034.

Who is the current CEO of Aurigene?

Murali Ramachandra of Aurigene.

How many employees does Aurigene have?

As of Aug 31, 2024, Aurigene has 495 employees, reflecting a 2% year-over-year growth in headcount.

Is Aurigene a funded company?

Aurigene is a funded company, having raised a total of $***** in its 1st and only funding round.

What is the annual revenue of Aurigene?

Annual revenue of Aurigene is ₹172Cr as on Mar 31, 2025.

Where does Aurigene rank among its competitors?

Aurigene ranks 470th amongst 3189 active competitors, of which 1090 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of Aurigene?

Aurigene's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

Aurigene - 2026 Company Profile, Team, Competitors & Financials

Aurigene is an unfunded company based in Bengaluru (India), founded in 2001. It operates as a Clinical-stage biotech company specializing in the discovery and development of novel therapeutics for cancer treatment. Aurigene has not raised any funding yet. The company has 3189 active competitors, including 1090 funded and 762 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma.

Company Details

Clinical-stage biotech company specializing in the discovery and development of novel therapeutics for cancer treatment. Leveraging its expertise in drug discovery and development to bring innovative solutions to the market.

Website: aurigene.com
Social
Email ID: *****@aurigene.com
Phone Number: +91 **********
Part Of
Registered Address: 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Hyderabad, Telangana, India, 500034

Key Metrics

Founded Year

2001

Location

Bengaluru, India

Stage

Unfunded

Ranked

470^th among 3189 active competitors

Annual Revenue

₹172Cr as on Mar 31, 2025

Employee Count

495 as on Aug 31, 2024

Investment & Acquisitions

Carditek Medical Devices

Similar Companies

Jazz Pharmaceuticals & 2956 more

View Aurigene's full profile

Aurigene is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AURIGENE ONCOLOGY LIMITED CIN: U24239KA2001PLC029391 , India, Active	Aug 10, 2001	$20.3M (As on Mar 31, 2025)	466 (As on Jan 31, 2025)
DR.REDDY'S LABORATORIES LTD CIN: L85195TG1984PLC004507 , India, Active	Feb 24, 1984	$3.99B (As on Mar 31, 2025)	13331 (As on Jan 31, 2025)

Aurigene has not raised any funding rounds yet.

Aurigene's employee count trend

Aurigene has 495 employees as of Aug 24. The total employee count is 2.0% more than what it was in Aug 23. Here is Aurigene's employee count trend over the years:

Uncover Aurigene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aurigene include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of Aurigene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
470th	Aurigene 2001, Bengaluru (India), Unfunded	Clinical-stage biotech company specializing in the discovery and development of novel therapeutics for cancer treatment	-	-	54/100